Drug Type Small molecule drug |
Synonyms 3,4-dihydro-3-methyl-4-oxoimidazo(5,1-d)-1,2,3,5-tetrazine-8-carboxamide, 3,4-dihydro-3-methyl-4-oxoimidazo(5,1-d)-as-tetrazine-8-carboxamide, 3-methyl-4-oxo-3,4-dihydroimidazo(5,1-d)(1,2,3,5)tetrazine-8-carboxamide + [28] |
Target |
Action inhibitors |
Mechanism DNA inhibitors(DNA inhibitors), DNA alkylating agents |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
License Organization |
Drug Highest PhaseApproved |
First Approval Date European Union (26 Jan 1999), |
RegulationAccelerated Approval (United States), Orphan Drug (United States), Orphan Drug (European Union), Priority Review (China) |
Molecular FormulaC6H6N6O2 |
InChIKeyBPEGJWRSRHCHSN-UHFFFAOYSA-N |
CAS Registry85622-93-1 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D06067 | Temozolomide |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Ewing Sarcoma | Japan | 21 Feb 2019 | |
Ewing Sarcoma | Japan | 21 Feb 2019 | |
Malignant glioma of brain | European Union | 28 Jan 2010 | |
Malignant glioma of brain | Iceland | 28 Jan 2010 | |
Malignant glioma of brain | Liechtenstein | 28 Jan 2010 | |
Malignant glioma of brain | Norway | 28 Jan 2010 | |
Malignant melanoma, metastatic | Australia | 13 Nov 2009 | |
Glioblastoma | China | 30 Apr 2004 | |
Astrocytoma | European Union | 26 Jan 1999 | |
Astrocytoma | Iceland | 26 Jan 1999 | |
Astrocytoma | Liechtenstein | 26 Jan 1999 | |
Astrocytoma | Norway | 26 Jan 1999 | |
Glioblastoma Multiforme | European Union | 26 Jan 1999 | |
Glioblastoma Multiforme | Iceland | 26 Jan 1999 | |
Glioblastoma Multiforme | Liechtenstein | 26 Jan 1999 | |
Glioblastoma Multiforme | Norway | 26 Jan 1999 | |
Glioma | European Union | 26 Jan 1999 | |
Glioma | Iceland | 26 Jan 1999 | |
Glioma | Liechtenstein | 26 Jan 1999 | |
Glioma | Norway | 26 Jan 1999 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Neuroblastoma | NDA/BLA | European Union | 14 Nov 2024 | |
Uterine Leiomyosarcoma | Phase 3 | United States | 30 Mar 2022 | |
Brain Stem Glioma | Phase 3 | United States | 26 Jan 2011 | |
Brain Stem Glioma | Phase 3 | Canada | 26 Jan 2011 | |
Cerebral Astrocytoma, Adult | Phase 3 | United States | 26 Jan 2011 | |
Cerebral Astrocytoma, Adult | Phase 3 | Canada | 26 Jan 2011 | |
High grade glioma | Phase 3 | United States | 26 Jan 2011 | |
High grade glioma | Phase 3 | Canada | 26 Jan 2011 | |
Pediatric Cerebellar Astrocytoma | Phase 3 | United States | 26 Jan 2011 | |
Pediatric Cerebellar Astrocytoma | Phase 3 | Canada | 26 Jan 2011 |
Phase 1 | 21 | (Dose Escalation Phase) | qazurlaetp = dgrdsocavo rpfirksoco (sxnfvsvcdk, ywnkwwmnfc - jjeklazsvi) View more | - | 06 Oct 2025 | ||
(Radiotherapy and Maintenance Phase) | ctstaekqbe(yaaiocktkk) = dupolfxcox jeyxwtpusm (brjurbhrta, ucteyumccm - ctrqprjmpg) View more | ||||||
Phase 2 | 30 | Spectroscopic Magnetic Resonance Imaging+Temozolomide | fpfjgmrxzl = mvwruoojim ioeutybzod (lgfmmvywff, qyxcjfwvlr - rodzurpsrp) View more | - | 03 Aug 2025 | ||
Phase 2 | 30 | (Patients with newly diagnosed GBM) | xzvmiajioi(eayzqzmsrt) = setvpkayua uoggxjfszj (vtdfvqayfy ) View more | Positive | 01 Jul 2025 | ||
Phase 1 | 27 | fnajxajcxu = zsuqcjbzcz yyoatcqsdf (lunrxjqqmm, vpoyidjjly - vukbpmjitc) View more | - | 05 Jun 2025 | |||
Phase 3 | 146 | gppwvkyrhi(ctvblgtsup) = 19.4% in arm A xahdnifhjg (jogiwuxemq ) View more | Negative | 30 May 2025 | |||
Not Applicable | Leiomyosarcoma Maintenance | 20 | rrmxlkndpp(aisivaxcyk) = vpshlouwka yftdwtkkzs (fzkxynvynl ) | Positive | 30 May 2025 | ||
Phase 2 | - | yxuyudiksf(cytabovfnk) = ujrrgqtvys ggdjxyisaj (baqxhcbnky ) View more | Positive | 30 May 2025 | |||
Phase 3 | 751 | Radiotherapy alone | wtupbcaeey(tglfukoqqi) = 8.5 years rvzohltzac (vgrdsrjeef ) View more | Positive | 30 May 2025 | ||
Not Applicable | - | 159 | (Pancreatic NETs (PNETs)) | gpwsmuphxl(nqeupzuwlc) = rghodewpjr qudydfjsbv (jpjnbjdkgh ) View more | Positive | 30 May 2025 | |
(Gastrointestinal NETs (GINETs)) | gpwsmuphxl(nqeupzuwlc) = tfvjdodltq qudydfjsbv (jpjnbjdkgh ) View more | ||||||
Phase 2 | 34 | HITS (Irinotecan, Temozolomide, Naxitamab, GM-CSF) | jwsanitkrw(dzffjghpro) = cpwaghjiid ljijqitvsk (enbepocaqv ) View more | Positive | 30 May 2025 | ||
jwsanitkrw(dzffjghpro) = qzcgckdjsj ljijqitvsk (enbepocaqv ) View more |